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Abstract
Background: The membrane cytoskeletal crosslinker, ezrin, a member of the ERM family of proteins, is frequently
over-expressed in human breast cancers, and is required for motility and invasion of epithelial cells. Our group
previously showed that ezrin acts co-operatively with the non-receptor tyrosine kinase, Src, in deregulation of cell-
cell contacts and scattering of epithelial cells. In particular, ezrin phosphorylation on Y477 by Src is specific to ezrin
within the ERM family, and is required for HGF-induced scattering of epithelial cells. We therefore sought to
examine the role of Y477 phosphorylation in ezrin on tumor progression.
Methods: Using a highly metastatic mouse mammary carcinoma cell line (AC2M2), we tested the effect of over-
expressing a non-phosphorylatable form of ezrin (Y477F) on invasive colony growth in 3-dimensional Matrigel
cultures, and on local invasion and metastasis in an orthotopic engraftment model.
Results: AC2M2 cells over-expressing Y477F ezrin exhibited delayed migration in vitro, and cohesive round colonies
in 3-dimensional Matrigel cultures, compared to control cells that formed invasive colonies with branching chains
of cells and numerous actin-rich protrusions. Moreover, over-expression of Y477F ezrin inhibits local tumor invasion
in vivo. Whereas orthotopically injected wild type AC2M2 tumor cells were found to infiltrate into the abdominal
wall and visceral organs within three weeks, tumors expressing Y477F ezrin remained circumscribed, with little
invasion into the surrounding stroma and abdominal wall. Additionally, Y477F ezrin reduces the number of lung
metastatic lesions.
Conclusions: Our study implicates a role of Y477 ezrin, which is phosphorylated by Src, in regulating local invasion
and metastasis of breast carcinoma cells, and provides a clinically relevant model for assessing the Src/ezrin
pathway as a potential prognostic/predictive marker or treatment target for invasive human breast cancer.
Background
Ezrin is a member of the ezrin-radixin-moesin (ERM)
family that functions as a cytoskeletal plasma membrane
crosslinker [1,2]. Ezrin is required for epithelial cell integ-
rity and participates in several actin-based functions such
as organization of the apical surface of epithelial cells
[3,4], cell adhesion [5,6], cell motility and morphogenesis
[3,7]. ERM proteins are negatively regulated by an intra-
molecular interaction between the N-terminal and
C-terminal domains, which masks the actin and mem-
brane binding sites [1]. Sequential binding of PIP2 and
phosphorylation of a conserved threonine residue (T567)
are required for ezrin activation and membrane-cytoske-
leton linker function [8].
Ezrin also plays an important role in tumor progres-
sion. Gene [9,10] and protein [11-17] expression profiling
have revealed a marked increase in ezrin expression in a
variety of human and rodent cancers compared to non-
malignant tissue counterparts. Moreover, increased cyto-
plasmic expression of ezrin is frequently associated with
dedifferentiation, invasiveness, and poor prognosis in
human breast cancers; compared to membranous apical
expression in non-malignant epithelial tissues [18].
Furthermore, suppression of ezrin function using shRNA
and dominant negative ezrin mutants abrogates invasion,
early metastatic survival, as well as lung metastases in
osteosarcoma, rhabdomyosarcoma [9,19], and breast
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any medium, provided the original work is properly cited.carcinoma [20-22] cell lines. In addition, ectopic expres-
sion of the suppressor gene, RhoBTB2, causes depho-
sphorylation of ezrin and inhibits migration and
metastasis of breast carcinoma cells [23].
Ezrin is a substrate of the non-receptor tyrosine kinase,
Src [2,5,24]. Src expression and activation are frequently
up-regulated in breast cancer, and Src is typically recruited
to both focal adhesions and cell-cell contacts. It is required
for anchorage-independent growth, cell migration and
invasion [25,26]. Activated pY419 Src has been found to
be associated with decreased disease-specific survival in
human breast cancer patients [27-29]. Over-expression of
an activated form of Src in transgenic mice induces mam-
mary hyperplasias, which infrequently progress to tumors
[30]. Furthermore, Src kinase is required for polyoma mid-
dle T-induced mammary tumorigenesis in transgenic mice
[31]. Using a mouse breast carcinoma cell line (SP1),
we have shown previously that c-Src kinase activity is
required for HGF-dependent cell motility and anchorage-
independent growth [32]. Collectively, these findings indi-
cate that c-Src kinase activity is an important requirement
for mammary tumorigenesis.
We and others have recently identified a co-operative
role of Src and ezrin in regulating disruption of cadherin-
based cell-cell contacts [33], cell spreading and cell mor-
phogenesis [5] in epithelial cells. Furthermore, Src/ezrin
co-operativity is regulated through phosphorylation of spe-
cific tyrosines (Y145 and Y447) on ezrin by Src [5,24].
Expression of Y145F or Y477F ezrin, mutants that cannot
be phosphorylated by Src, delays HGF-induced cell
spreading of epithelial cells on fibronectin substratum.
Naba et al. [2,6] further showed that interaction of Fes
kinase with pY477 of ezrin promotes HGF-induced scat-
tering of epithelial cells, suggesting the ezrin/Fes interac-
tion is linked to epithelial-mesenchymal transition [2,6]. In
addition, Heiska et al. [34] have recently shown that Y477
ezrin is required for growth and invasion of Src-trans-
formed fibroblasts in 3-dimenional (3D) matrix cultures.
However the role of ezrin phosphorylation on tyrosine 477
in tumor progression and metastatic dissemination
remains unknown.
Based on the above findings, we hypothesized that phos-
phorylation of Y477 on ezrin by Src, could regulate the
invasive and metastatic potential of mammary carcinoma
cells, and thus breast tumorigenesis and progression.
Using a model of orthotopic engraftment of a mouse
mammary carcinoma tumor cell line (AC2M2) [20], we
found that over-expression of a nonphosphorylatable
Y477F ezrin mutant markedly decreased local invasion of
primary tumor transplants, compared to control vector
expressing tumor transplants which rapidly infiltrated into
underlying abdominal wall and visceral tissues. In support
of these observations, Y477F ezrin-expressing AC2M2
cells formed cohesive round colonies with few cellular
extensions in 3-dimensional (3D) Matrigel cultures, com-
pared to control vector expressing cells which showed
marked invasion of branching chains of cells with numer-
ous actin-rich protrusions. Altogether, these findings
implicate a pivotal regulatory role of the Src phosphoryla-
tion site, Y477, on ezrin in invasion and dissemination of
breast cancer cells.
Methods
Cell lines and tissue culture
The AC2M2 cell line is a lung metastatic variant
selected from a breast carcinoma cell line (SP1) follow-
ing serial intramammary injections of lung metastatic
nodules into syngeneic mice, as described previously
[35]. The AC2M2 cell line was maintained in Dulbecco’s
modified Eagle medium (DMEM, Invitrogen/Gibco, Bur-
lington, ON) with 10% fetal bovine serum (FBS) at 37°C.
Cell transfection
The pCB6 vector containing cDNA coding for Y477F
ezrin fused to the VSVG tag was previously described [6].
Transfections with pCB6 alone or containing VSVG
tagged Y477F ezrin were carried out with Lipofectamine
Plus reagent (Invitrogen/Gibco) in accordance with the
recommended protocol. Stable transfectants were selected
for G418 resistance (400 μg/ml; Invitrogen:Gibco) and
cloned. One pCB6 clone and two Y477F ezrin-expressing
clones (A43 and C13) were selected for further study.
Western blotting
Snap frozen tissues were homogenized in ice cold RIPA
buffer containing a cocktail of protease and phosphatase
inhibitors (Fisher Scientific, Tornonto, ON). Homoge-
nates were sonicated for 15-20 minutes at 4°C, and
centrifuged at 13000× rpm for 10 minutes at 4°C. The
supernatant was removed and the pellet was discarded.
Cultured cells were rinsed with ice-cold PBS supplemen-
ted with 0.1 μmol/l CaCl2 and 0.1 μmol/l MgCl2, and
lysed in 2× Laemmli buffer. Protein determination of
lysates was performed using a DC protein assay kit
(Biorad, Mississauga, ON). In one experiment involving
pY477 ezrin western blotting, cells were treated with
0.1 mM pervanadate for 5 min before lysis to inhibit
phosphatases [6]. All lysates were resolved on 8% polya-
crylamide gels for SDS-PAGE under reducing conditions
and transferred to PVDF membranes (Immobilon-P
membrane, Fisher Scientific). Membranes were blocked
and probed with the indicated primary antibodies and
appropriate secondary antibodies. Proteins were visua-
lized using enhanced chemiluminescence reagent (Pierce
ECL, Fisher Thermo Scientific, Toronto, ON). Densito-
metric analysis was used to calculate the ratio of ezrin to
g-tubulin, and the value for each clone was normalized to
that of pCB6 cells.
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Cells were plated in 12 well tissue culture plates (InVitro-
gen/Gibco) with complete tissue culture medium for next
day confluence, wounded and washed, as described pre-
viously [20]. Cell migration was monitored over a 24 h
period through a Nikon inverted microscope, and images
of the same marked fields were captured at various times.
The area of wound closure, relative to t = 0 hours was
measured in four independent wound sites per cell line
using ImageJ software. Relative cell motility was calcu-
lated as the difference between the wound area at t = 0
hours and t = 18 or 24 hours, as indicated. Mean values
+/- SD per group were calculated, and statistical signifi-
cance among groups was assessed using one-way analysis
of variance (ANOVA).
3D Matrigel cultures
3D Matrigel embedded cultures were set up as previously
described by Lee et al. [36]. Pre-chilled 8 chamber glass
cover slip plates (VWR/BD Biosciences, BD Biosciences,
Burlington, ON) were coated with a thin layer (30 μl) of
100% growth factor-reduced Matrigel (VWR/BD Bios-
ciences), and incubated at 37°C for at least 30 min to
allow for gelling. AC2M2 clones (7500 cells/well) expres-
sing pCB6 vector alone, or with Y477F ezrin, were har-
vested, resuspended in 75% Matrigel with complete
medium (DMEM/F12 + 5% FBS + 1% P/S + 5 μg/ml Insu-
lin), plated (150 μl/well) onto the coated surface, and
allowed to gel for 30 min at 37°C. 5% Matrigel was added
to the remaining chilled complete medium, for top up of
cultures (200 μl/well) and subsequent feeding every two
days. Cultures were monitored over a 12 day period, dur-
ing which time tumor cells formed clusters from single
cells, referred to subsequently as “colonies”, as previously
described [36,37]. Phase contrast photographs of colonies
were taken at various times using an inverted Olympus
microscope. The number of colonies per well was counted,
and colony forming ability was calculated as the percen-
tage of colonies formed from 7.5 x 103 cells plated per
well (average of 3 wells per group). Morphology of colo-
nies was assessed as “invasive” structures with branching
chains of cells (extensions) and cellular protrusions, or
cohesive “round” colonies with no chains or protrusions.
The presence of 5 or more cellular extensions or protru-
sions per colony was considered positive. At least 300
colonies were counted per group. Statistical significance
among groups was determined by one-way ANOVA.
Cell growth assay
Cell growth in vitro was assessed using an MTT
(Methylthiazolyldiphenyl-tetrazolium) assay (Sigma-
Aldrich, Oakville, Ontario), according to manufacturer’s
specifications. See Additional file 1: Figure S1 for details.
Immunofluorescence
Cell colonies from Matrigel cultures were fixed in the
chamber wells with a final concentration of 4% parafor-
maldehyde in PBS for 30 min, permeabilized with 0.5%
Triton X100 for 15 min, and blocked for 1.5 h in immuno-
fluroescence (IF) buffer (130 mM NaCl, 7 mM Na2HPO4,
3.5 mM NaH2PO4, 7.7 mM NaN3, 0.1% BSA, 0.2% Tri-
ton-X 100, 0.05% Tween 20) with 10% goat serum. Cells
were stained for 2.5 h at 4°C with rabbit anti-ezrin and
anti-VSVG antibodies (prepared as previously described
[38]). Cells were then washed 3 times with IF buffer, incu-
bated for 1 h with Alexa546 anti-rabbit IgG (Invitrogen),
washed 3 times with IF buffer, followed by DAPI staining
for 15 min, and rinsing with PBS. In some experiments,
Alexa488-phalloidin (Invitrogen/Gibco) was used to detect
F-actin. Preparations were imaged using a Quorum Wave
FX spinning disk confocal microscope (Quorum Technol-
ogies, Inc.) in the Queen’s Cancer Research Institute and
Protein Discovery and Function Facility. 3D reconstruction
of deconvoluted image stacks was carried out using Meta-
morph imaging software (Molecular Devices, Inc., Sunny-
vale, CA). Images shown are representative of at least 20
colonies in three experiments.
Tumor transplantation
In this model, we have previously shown that 100% inci-
dence of primary tumor takes occurs in mice engrafted
into the mammary gland with 7.5 × 103 tumor cells, with
tumor diameter reaching 1 cm within an average of
27 days. AC2M2 cells were injected (7.5 × 103 cells in
10 μl/mouse) into the mammary fat pad of athymic female
nude (nu-/-) mice (Tac: NCRNUM, Taconic Farms), as
described previously [20]. Immunodeficient nude mouse
recipients were used to minimize the T cell-dependent
effects of the immune system on tumor growth and
metastasis, and to allow assessment of tumor lesions (e.g,
shape, texture, and adhesion to abdominal wall) in real
time during early stages of tumor growth. Mice were
housed in the Animal Care Facility and procedures were
carried out according to the guidelines of the Canadian
Council on Animal Care, with the approval of the institu-
tional animal care committee. Control tumors engrafted
into the mammary fatpad of nude mice showed a similar
pattern of metastatic spread as previously found with the
syngeneic engraftment model [20]. Primary tumor growth
was monitored and measured with callipers every 2-3
days. Perpendicular dimensions were measured and tumor
volume was calculated using the following formula: (a)
(b2)/2; where ‘a’ was the larger of the two measurements.
The natural log of the tumor volumes as measured on
days 15, 17, 20, and 23 (representing a logarithmic growth
period) was compared among the groups by a linear
mixed effect model [39], and significance was assessed
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tional file 2: Figure S2).
Primary tumors were surgically removed at 21 and 23
days (in 2 experiments, respectively), at which time tumor
diameters were close to 1 cm and local invasion was
observed. Animals were allowed to recover, and were
monitored for 20 more days to allow distant metastases to
grow and to assess local recurrence, as determined pre-
viously [35]. Gross pathology of resected primary tumors,
as well as abdominal and thoracic (lung) organs, and ingu-
inal, axillary and iliac lymph nodes removed at autopsy
was assessed. Portions of tissues were either snap frozen
for biochemistry, or fixed in 4% paraformaldehyde and
paraffin embedded (FFPE). Fixed tissue sections (5 μm
thickness) were stained with hematoxylin and eosin to
assess primary tumors, abdominal and thoracic organs for
presence of local invasion and metastases. Six mice were
included in each group of two experiments, and results
were combined for analysis.
Scoring and analysis of local invasion and metastasis
Local invasion was defined at the gross pathological level
primarily as adhesion to, or invasion of tumor cells into,
the adjacent abdominal muscle wall. At the histological
level, tumors were classified as non-invasive if a clear cir-
cumscribed border between the tumor and the stroma
was observed. Tumors that were invasive often displayed
tumor extensions into the surrounding fatpad, and spread-
ing into the abdominal wall or draining lymph node. Seed-
ing of tumor cells and invasion into visceral organs was
also recorded. Invasion based on any of the above criteria
was assessed as a categorical factor (presence or absence),
and a two-sided non-parametric Fisher exact test was used
to assess statistical significance among control pCB6 and
Y477F ezrin-expressing clones.
For metastasis assessment,l u n g sf r o mt u m o rb e a r i n g
mice were processed as described above, and 5 μms e r i a l
sections of paraffin embedded tissues were stained with
hematoxylin and eosin for histopathological examination.
At least two sections from the superficial and middle
regions of each mouse lung were examined, and the num-
ber of lung nodules per mouse was determined. The pro-
portion of mice with metastases (positive or negative) in
each group was tabulated with significance determined by
a two-sided Fisher exact test. The frequency of lung
lesions (number of lung nodules) for each mouse in each
group is shown as a dot plot, with significance determined
by a non-parametric Wilcoxon Rank Sum test.
Results
Expression of Y477F ezrin mutant attenuates migration of
breast carcinoma cells
Since cell migration is an important early step in tumor
invasion, we examined the role of Y477 ezrin on migration
function of a highly metastatic carcinoma variant cell line,
AC2M2, derived from the mouse mammary tumor cell
line, SP1 [35]. SP1 and AC2M2 cells express HGF and
activated Met, and spontaneously migrate in a wound
healing assay ([40], unpublished data). We generated
stable transfectants of AC2M2 cells expressing either a
VSVG-tagged Y477F ezrin mutant in a pCB6 eukaryotic
expression vector (clones A43 and C13), or an empty vec-
tor (control) (Figure 1A). A VSVG-tagged protein corre-
sponding to the 80 kDa ezrin band was detected in both
A43 and C13 cells. Total ezrin protein levels were approxi-
mately 3-fold higher in A43 and C13 clones compared
with the pCB6 clone, indicating overexpression of Y477F-
ezrin compared to endogenous protein. Likewise, phos-
phorylated T567 ezrin (upper band) showed increased
expression in Y477F ezrin compared to pCB6 clones,
while phosphorylated T568 moesin remained unchanged.
Endogenous levels of pY477 were similar among the three
cell clones.
AC2M2 cells expressing Y477F ezrin showed a signifi-
cantly reduced rate of wound closure at 18 h and 24 h,
compared with control cells which spontaneously migrate
(Figure 1B, C). Less than confluent cultures showed no
significant effect of Y477F ezrin on wound closure, indi-
cating that the observed phenotype was dependent on cell
density (data not shown). Thus expression of Y477F ezrin
attenuates migration of confluent breast carcinoma cells.
Y477F ezrin mutant inhibits invasion of breast cancer
cells in 3D Matrigel culture
Since tumor cell invasion is affected by the 3D matrix
milieu [41], we decided to further characterize the Y477F
ezrin phenotype in a 3D Matrigel embedded culture sys-
tem [36]. Interestingly, AC2M2 cells expressing control
vector or Y477F ezrin (clones A43 and C13) showed no
significant difference in overall cell growth or colony
forming ability in 3D Matrigel cultures (Additional file 1:
Figure S1). However the morphology of the Y477F ezrin
compared to control groups was quite distinct (Figure 2).
By 12 days, control cells formed predominantly (91%)
colonies with branching chains of cells (extensions)
and cellular protrusions, characteristic of a migratory
invasive phenotype. In contrast, the majority (92-96%) of
Y477F ezrin cells formed colonies exhibiting a cohesive
round morphology with very few cellular extensions or
protrusions.
To assess the architectural organization of cell colonies
in 3D culture, expression and localization of total ezrin,
Y477F-ezrin (VSVGtagged)and F-actin were examined
using confocal spinning disk microscopy and deconvolu-
tion image analysis. 3D projection images of pCB6 cell
colonies confirmed the presence of branching chains of
cells, characteristics of invasive breast carcinoma cells
[37,42] (Figure 3A). Moreover, the distal leading cells
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Figure 1 Effect of Y477F ezrin on cell motility in AC2M2 cells: Panel A) AC2M2 cells transfected with an empty pCB6 vector, or expressing
Y477F ezrin, clones (A43 and C13) were lysed in Laemmli buffer, and equal protein amounts were subjected to SDS-PAGE and western blotting
with antibodies against VSVG, ezrin, pY477 ezrin, pTERM and g-tubulin. In the ezrin blot, the ~81 kDa band in pCB6 represents endogenous ezrin,
while the bands in A43 and C13 represent both Y477F mutant and endogenous ezrin. Optical density (OD) ratios of ezrin vs g-tubulin bands
show a 2.6-fold and 3.5-fold increase in total ezrin expression of the A43 and C13 clones, respectively, normalized to the pCB6 clone. Ezr, ezrin;
moe, moesin. Panel B) AC2M2 clones expressing either pCB6 empty vector or Y477F ezrin were grown to confluence in 10% FBS/DMEM.
Confluent cells were wounded by scoring and medium was immediately replaced. Spontaneous wound closure at each of four marked wound
sites for each cell clone was monitored for up to 24 h by phase contrast microscopy. The histogram shows relative cell motility for each clone
calculated as the area of wound closure at 18 h and 24 h compared to T = 0 h. Values represent the mean +/- SD of 4 wound sites per clone in
each of two experiments. There was significant reduction in cell motility in Y477F ezrin expressing clones (A43 and C13) at both 18 h and 24 h,
as determined by a one-way ANOVA (p < 0.001). Panel C) Representative fields photographed using phase contrast microscopy (10× objective)
at 0 h, 18 h and 24 h are shown. Boxed areas indicate wound area measured at each time point.
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Page 5 of 14showed numerous actin-rich cellular protrusions, charac-
teristics of migratory cells. Ezrin was strongly localized in
these actin-rich structures, and weakly expressed in the
central region of pCB6 colonies (Figure 3C, D). In con-
trast, the colonies formed by Y477F ezrin expressing cells
exhibited a cohesive round morphology and failed to form
chains or protrusions, resulting in an overall smooth
surface (Figure 3B, E). In these colonies intense actin
staining was evident in the cortical cellular region (Figure
3F). Furthermore, both ezrin and VSVG (Y477F) ezrin
showed a partial membranous staining which was stron-
gest in the outer surface of colonies of Y477F ezrin expres-
sing cells, though some diffuse cytoplasmic staining was
also evident (Figure 3E). XY plane images through the
**pCB6 compared to A43 or C13 is significant (One way ANOVA, p < 0.001). 
Proportion of aggregates with or without branching extensions after 10 days 
A. 
B. 
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Figure 2 Effect of Y477F ezrin on morphology of AC2M2 cells in 3D Matrigel cultures: Panel A: AC2M2 cell clones expressing pCB6 empty
vector or Y477F ezrin (clones A43 and C13) were cultured in 3D Matrigel. Colony morphology was assessed at the times indicated, using phase
contrast microscopy. Objective magnification is shown in each panel. Panel B: Table indicates percentages of invasive colonies from each cell
clone with branching cellular extensions and protrusions, and of cohesive round colonies with no extensions, respectively. The presence of 5 or
more cellular extensions or protrusions per colony was considered positive. Mean percentage of colonies +/- SD (3 wells per group) in each
category is shown. N = total number of colonies counted. pCB6 cells formed predominantly invasive colonies with cellular extensions, whereas
the majority of Y477F ezrin cells formed round colonies with no extensions. The above differences in colony morphology were significant as
determined by one way ANOVA (p < 0.001).
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revealed no hollow lumens (Figure 3D, E). Thus, the pre-
sence of actin-rich cellular protrusions with marked ezrin
expression is a distinguishing feature of pCB6-expressing
colonies, while the expression of Y477F ezrin inhibited
this invasive phenotype.
Y477F ezrin inhibits local invasion but not growth of
primary tumor outgrowths
Our finding that Y477F ezrin attenuates the invasive
tumor phenotype in 3D Matrigel cultures in vitro
prompted us to assess the effect of Y477F ezrin on in
vivo tumor progression using our highly metastatic
AC2M2 carcinoma cell line model [20]. AC2M2 cell
clones expressing control vector or Y477F ezrin were
engrafted into the mammary gland of recipient mice and
primary tumor growth was monitored every 2-3 days.
Primary tumors were excised at 21 or 23 days (two
experiments), at which time lesions were close to 1 cm in
diameter. A VSVG-tagged 80 kDa protein was detected
by western blotting on protein extracts from Y477F ezrin
expressing tumors, indicating the presence of the mutant
ezrin form in the tumor tissues. (Additional file 2: Figure
S2A). No significant difference in mean tumor volume
per group between pCB6 control and Y477F ezrin-
expressing tumors over days 15, 17, 20 and 23 (represent-
ing a logarithmic growth period) was observed (overall
p = 0.57) (Additional file 2: Figure S2B).
Local invasion and spreading of pCB6 control and
Y477F ezrin expressing AC2M2 tumors were character-
ized based on gross and histopathological assessment of
primary lesions excised after 21-23 days (corresponding to
Additional file 2: Figure S2B). At this time control tumors
are locally invasive but overt metastases in distant organs
are not yet visible. On gross pathological examination, the
majority (11/12) of pCB6 control tumors were found to
invade through the abdominal wall and underlying muscle
(Figure 4A), with tumor nodules frequently visible in visc-
eral organs (Additional file 3: Figure S3). Histopathological
analysis of excised primary tumor tissues confirmed that
the majority of pCB6 tumors had invaded into the sur-
rounding mammary fatpad, underlying abdominal muscle
and adjacent lymph node (Figure 4B, C). Seeding of tumor
cells in the viscera, disseminating into various abdominal
organs via peritoneal spread, was also confirmed (Addi-
tional file 3: Figure S3). Variable organ involvement
included intestine, pancreas and spleen. In a rare instance,
a suggestive perineural invasion was seen in one of the
pCB6 control tumors. Thus, extensive local invasion and
seeding of visceral organs by pCB6 control tumors was
clearly visible. In contrast, few of the Y477F ezrin expres-
sing tumors (6/24, pool of two independent clones)
showed local invasion or seeding of visceral organs at the
same time point (Figure 4D-F). Moreover, the majority of
Y477F ezrin tumors remained circumscribed, with no
invasion into surrounding stroma or adhesion to the
abdominal wall (p = 0.0002, two-sided Fisher Exact test)
(Figure 4G). These results show that Y477F ezrin attenu-
ates local invasion of AC2M2 tumor cells following
engraftment into the mammary fatpad.
Y477F ezrin reduces the frequency of lung metastatic
lesions in tumor engrafted mice
To assess the effect of Y477F ezrin on distant metastasis,
mice were allowed to survive for an additional 20 days fol-
lowing excision of primary tumors expressing pCB6 or
Y477F ezrin (clones A43 and C13) to allow outgrowth of
lung metastases. The presence of lung metastases was
assessed by histological examination of serial tissue sec-
tions stained with hematoxylin and eosin, as described in
Materials and Methods (see also Additional Additional
file 3: Figure S3G-H). Although there was a trend towards
a reduced incidence of lung metastases in mice bearing
Y477F ezrin tumors (both A43 and C13 clones), this dif-
ference did not achieve significance (p = 0.07, Figure 5A).
However, when the number of lung nodules per mouse
was assessed, the frequency of lung metastatic lesions was
significantly reduced in mice with clone A43 tumors (p =
0.0129) (Figure 5B). While fewer lesions in mice with
clone C13 tumors were also observed, this difference was
not significant (p = 0.0853) due to one outlier mouse (with
8 nodules). However, analysis of pooled results showed
that the frequency of lung lesions from both Y477F ezrin
clone tumors (A43 and C13) was significantly reduced,
compared to pCB6 tumors (p = 0.0131). Thus, ectopic
expression of Y477F ezrin significantly reduces the fre-
quency of lung metastatic lesions following orthotopic
engraftment of AC2M2 tumor cells into the mammary
fatpad.
Discussion
Our previous demonstration of Src/ezrin co-operativity
[33], and the required Y477 phosphorylation of ezrin by
Src in HGF-induced scattering of epithelial cells [6],
prompted us to examine the role of Y477 ezrin in primary
tumor growth, local invasion and metastasis in an in vivo
model of malignant breast cancer. Y477 is of particular
interest since this residue is specific for ezrin and is not
present in the two other ERM proteins, radixin or moesin,
that are highly homologous to ezrin [2,6]. In this report,
we show for the first time that Y477F ezrin attenuates
local invasion and distant metastasis of breast carcinoma
cells transplanted into the orthotopic site of recipient
mice. Moreover, Y477F ezrin promotes formation of
round colonies by carcinoma cells embedded in 3D Matri-
gel culture, compared to formation of invasive colonies by
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http://www.biomedcentral.com/1471-2407/12/82
Page 7 of 14F. 
Figure 3 Cellular localization of ezrin and Y477F ezrin (VSVG tagged) in colonies growing in 3D Matrigel culture: Colonies formed from
AC2M2 cells expressing pCB6 control vector or Y477F ezrin (clone C13) in day 12 embedded Matrigel cultures (see Figure 2) were fixed, and
stained for ezrin (red), actin (green, phalloidin), and nuclei (blue, DAPI). Images of stained colonies were acquired using a Quorum Wave FX
spinning disk confocal microscope. Panels A & B) 3D projection images of pCB6 control and Y477F ezrin expressing clones are shown (three
colours merged). Inserts show single XY plane of actin-rich cellular protrusions with ezrin localized to the cytoplasmic side in pCB6 colonies. No
actin-rich protrusions were evident in Y477F ezrin colonies. Panel C) Images of pCB6 colonies were deconvoluted and subjected to 3D
reconstruction using Metamorph software. A middle section showed strong localization of ezrin in cellular extensions, compared to weak
expression in the central core of colonies. Panel D) A middle xy plane of the pCB6 colony shown in C confirmed the absence of a hollow
lumen. Panel E) Deconvoluted images of Y477F ezrin expressing colonies stained for ezrin or VSVG were subjected to 3D reconstruction as
above. A middle xy plane showed a partial membranous staining which was strongest in the outer surface of colonies of Y477F ezrin-expressing
cells, though some diffuse cytoplasmic staining was also evident. No hollow lumens were present. Panel F) XY planes corresponding to ezrin
and VSVG staining in E show actin structures associated with the plasma membrane particularly at cell junctions. Images are representative of at
least 20 colonies examined in each group. Scale bar indicates 50 μm.
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C13  Y477F ezrin  3/12 p=0.003* 
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*Two-sided Fisher Exact test 
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Figure 4 Effect of the expression of Y477F ezrin on local invasion of AC2M2 breast carcinoma cells: Two clones of AC2M2 cells
expressing Y477F ezrin (A43 and C13) or empty pCB6 vector were engrafted into the mammary fat pad of nude mice. Primary tumors from the
mice were excised after 21 or 23 days, and photographs of gross pathology (Panels A, D) were taken. Scale bar = 0.5 cm. 5 μm sections of FFPE
processed tissues were stained with hematoxylin and eosin for histopathological analysis. Arrows indicate invasion of pCB6 tumor into
underlying abdominal muscle wall (Panels A, B) or draining lymph node (Panel C). In contrast, Y477F ezrin tumors showed no adhesion to
abdominal wall (Panels D, E) and rarely penetrated into the circumscribed tumor margin (Panel E) or adjacent lymph node (Panel F). Invasion
was assessed categorically (presence or absence), based on combined observations of gross and histopathology. Data were expressed as the
proportion of mice with local invasion relative to the total number of mice per group. Significant difference between pCB6 control and Y477F
ezrin-expressing clones (A43 and C13) in two pooled experiments is shown (p = 0.003, two-sided Fisher Exact test). The overall p value for A43 +
C13 clones combined is 0.0002 (Panel G). Label with “T” indicates tumor, “Mus” indicates muscle and “LN” indicates lymph node. Image
magnification is shown in each panel.
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A43 + C13 
combined 0.0131*
Wilcoxon Rank Sum test:
*Significant reduction compared to pCB6 group 
Figure 5 Effect of the expression of Y477F ezrin on lung metastasis formation. Mice from which primary tumors were removed
(corresponding to Additional file 2: Figure S2) were allowed to survive for 20 additional days to allow overt metastases to form. Serial sections (5
μm) of FFPE processed lung tissues were stained with hematoxylin and eosin for histopathological assessment. At least two sections from the
superficial and middle planes, respectively, of each mouse lung were examined and the number of lung nodules per mouse was determined.
Panel A) The table shows the proportion of mice with metastasis in each group. The incidence of mice with lung metastases from Y477F ezrin
tumors (A43 and C13 clones) was reduced, but this difference did not achieve significance, as determined by a two-sided Fisher Exact test.
Panel B) The number of lung nodules per mouse per group is represented as a dot plot. Statistical significance was determined by a Wilcoxon
Rank Sum test. Mean +/- 95% confidence intervals (bars) is shown for each group. A significant reduction in the number of nodules per mouse
with clone A43 tumors was observed (p = 0.0129). The number of lung nodules in C13 tumors was also reduced, but this value was not
significant (p = 0.0853), due to one outlier. Analysis of pooled data showed a significant reduction in lung nodules in mice with A43 and C13
tumors combined, compared to mice with pCB6 tumors (p = 0.0131).
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Page 10 of 14control cells. Thus, phosphorylation of Y477 ezrin plays a
key role in local invasion and metastasis from the primary
tumor site.
The AC2M2 breast carcinoma cell line expresses ele-
vated Src activity, spontaneously migrates, invades through
transwell cultures, and metastasizes to the lung following
engraftment into the mammary fat pad [20,32]. An
approximate 3-fold over-expression of Y477F ezrin com-
pared to endogenous ezrin was sufficient to block sponta-
neous migration of AC2M2 cells in a wound healing assay,
consistent with a dominant inhibitory effect of the ezrin
mutant. Therefore the AC2M2 cell line model is ideally
suited for studying regulation of malignant breast tumor
progression by phosphorylatable Y477 ezrin.
Our observed invasive colonies of pCB6 cells with cellu-
lar extensions and protrusions in 3D Matrigel cultures is
similar to the aggressive “stellate” morphology identified
by Han et al. in certain human breast cancer cell lines (e.g.
MDA-MB-231) with basal-like characteristics [42]. In con-
trast, AC2M2 cells expressing Y477F ezrin formed predo-
minantly round colonies with no cellular extensions or
protrusions. However, cell growth and lumen filling was
unaffected, indicating a partial reversion of the malignant
phenotype that has been described as “cyst-like” by others
[37,43].This cyst-like phenotype is similar to the “round”
morphology identified by Han et al. [42], and has been
shown to be associated with less aggressive cancers. Gene
signatures corresponding to these morphologic pheno-
types were shown to accurately predict clinical outcome in
independent datasets of human breast cancers [44].
The presence of numerous actin-rich cellular protru-
sions, in which ezrin is localized in pCB6 colonies, is con-
sistent with the previously reported localization of ezrin in
invasive cancers [45,46]. In contrast, Y477F ezrin colonies
showed no actin-rich protrusions, indicating a loss of inva-
sive function; while strong actin staining in the cortical
region of cells was evident. Together, these findings are
consistent with previous reports that Y477F ezrin pro-
motes increased cell-cell contacts and inhibits HGF-
induced cell scattering in kidney epithelial cells [2,6].
Interestingly, pCB6 cells expressed low E-cadherin levels
and undetectable N-cadherin, and lacked robust cell-cell
adhesion ([20], data not shown). This lack of cadherin
engagement and reduced cell-cell contacts is frequently
associated with more aggressive human breast cancers
such as the basal-like subset [47].
In our in vivo mammary tumor progression model,
gross pathology and histological analysis showed that the
majority (> 90%) of primary control tumors engrafted
into mammary fatpads of recipient mice invaded into
surrounding fat tissue and underlying abdominal muscle
within 21 days post engraftment. In addition, marked
seeding and dissemination into visceral organs including
intestine, spleen, and pancreas were frequently evident.
One example of perineural invasion which occurs in
about 10% of human invasive breast cancer cases [48],
was also observed. Thus, control tumors displayed a phe-
notype similar to clinically advanced human breast can-
cers, where locally invasive primary tumors tend to
anchor to the chest wall and invade into underlying
muscle tissue [49].
In contrast to control tumors, few (25%) of the Y477F
ezrin tumors showed locally invasive characteristics. The
majority of Y477F ezrin tumors remained circumscribed,
with little invasion into surrounding stroma and abdom-
inal wall. Interestingly, no significant effect of Y477F ezrin
on the rate of primary growth of AC2M2 tumors was
observed, thus mimicking the effect of this mutant on the
growth behaviour of AC2M2 cells in 3D culture. This
novel finding suggests that phosphorylation at a single tyr-
osine residue (Y477) on ezrin plays a critical role in local
invasion of tumor cells, while having no detectable effect
on primary tumor outgrowth.
While Y477F ezrin was found to have a marked attenu-
ating effect on local invasion during early phases of tumor
growth, a reduction in the proportion of mice with distant
metastasis was also observed, though this effect failed to
reach significance. However, a significant reduction in the
frequency of lung lesions, an indication of metastatic
tumor load, was observed in Y477F ezrin clones compared
to pCB6 control cells. These findings show that Y477F
ezrin significantly reduces metastatic efficiency, perhaps
due to reduced rate of release of tumor cells from the pri-
mary lesion, reduced extravasation, or decreased efficiency
in establishing colonies in distant organs. The presence of
residual metastases in a small proportion of mice bearing
Y477F ezrin-expressing tumors could indicate alternate
routes of dissemination independent of Y477 ezrin
function.
The mechanism by which pY477 ezrin regulates tumor
invasion in AC2M2 cells is not known. However, recent
evidence shows that Src interaction via phosphorylation
of Y477 ezrin regulates HGF-induced scattering and
tubule formation in porcine kidney epithelial cells grown
in 3D collagen gels (data not shown, and [6]). In this
model, pY477 of ezrin interacts with Fes kinase, causing
its activation and localization to cell-cell contacts, and
phosphorylation by Fes of junctional proteins–a neces-
sary step for cell scattering. We can hypothesize that in
our model, the formation of round colonies observed in
3D matrigel when Y477F ezrin is expressed could be due
to the lack of interaction with binding partners such as
Fes. Similarly, the absence of actin-rich protrusions in
cells expressing Y477F ezrin could be due to the lack of
interaction between ezrin and currently unidentified
partners involved in actin cytoskeleton reorganization.
Moreover, pY477 of ezrin may act via pathways that con-
nect Src to receptor tyrosine kinases such as Met,
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Page 11 of 14resulting in invasive properties of tumor cells [2]. Consis-
tent with this concept is our recent demonstration of
Src/ezrin co-operativity in breast epithelial cells through
increased Met activation and degradation of matrix sub-
stratum, characteristic of the invasive phenotype [50].
Further studies are required to elucidate the role of Src/
ezrin pathway and Y477 ezrin phosphorylation in the
invasion process.
Conclusions
In the present study, we show for the first time that a
single tyrosine-to-phenylalanine substitution (Y477F) in
ezrin markedly attenuates local invasion and distant
metastasis of breast cancer cells from the primary tumor
site. Phosphorylation of Y477 ezrin by Src is required
for HGF-induced scattering [6]. Y477 is also unique to
ezrin, thus distinguishing the observed Src/ezrin synergy
effect from other ERM protein interactions. Therefore,
our study implicates a unique role of Src/ezrin in regu-
lating local invasion of breast carcinoma cells, and pro-
vides a clinically relevant model for assessing the
potential of this pathway as a prognostic biomarker or a
predictive marker for treatment response or relapse.
Additional material
Additional file 1: Figure S1. Effect of Y477F ezrin on growth of AC2M2
cells in 3D Matrigel cultures. Panels A and B) AC2M2 cell clones
expressing pCB6 empty vector or Y477F ezrin (clones A43 and C13) were
cultured in 3D Matrigel. Representative phase contrast images of 9 day
cultures of clones pCB6 (A) and C13 (B) photographed with a 4x
objective are shown. Panel C) AC2M2 cell clones described above were
cultured in 96 well plates (104 cells/100 μl/well) with 20% Matrigel,
supplemented with Phenol Red-free complete DMEM medium. After 3
days, an MTT assay was performed according to the manufacturer’s
instructions. Values represent mean O.D. (Absorbance at 570 nm) of 4
wells +/- SD. No significant difference in growth was detected as
determined by one way ANOVA (p = 0.319). Panel D) The number of
colonies per well in 9 day cultures described in A and B was counted
visually using phase contrast microscopy, and plotted as the mean of
three wells +/- SD. The colony forming ability (% colonies per 7.5 x 103
cells plated) for each group is indicated. A marginal increase in colony
forming ability was apparent in A43 and C13 (perhaps due to some
clustering of more diffuse pCB6 colonies), but this difference was not
significant as determined by one way ANOVA.
Additional file 2: Figure S2. Effect of the expression of Y477F ezrin on
primary tumor growth: Mice injected in the mammary fat pad with
AC2M2 cell clones (pCB6, A43, C13) in Figure 2 were monitored every
two days, and palpable tumors were measured using Vernier calipers.
Primary tumors were excised after 21-23 days, and mice were allowed to
live for 40 days (20 days post-resection of the primary tumor). Panel A)
Equal protein amounts of primary tumor tissue lysates were subjected to
SDS-PAGE. Western blotting was performed using antibodies against
VSVG, ezrin and g-tubulin. Mean optical density ratios of ezrin vs gtubulin
bands for the three tumor groups (0.52, 0.55 and 0. 64) showed no
significant difference, most likely due to host tissue contribution to the
total ezrin pool. Panel B) Primary tumor volumes in each group were
plotted as a function of days post engraftment. The mean +/- one
standard deviation (bars) is indicated for each group (pCB6, A43, C13)
at each time point. The natural log of the tumor volumes as measured
on days 15, 17, 20, and 23 was compared among the groups by a linear
mixed effect model as estimated by restricted maximum likelihood using
the SAS MIXED procedure (SAS Institute Inc., 2008). A first order
autoregressive correlation structure was used to account for within
mouse dependence [39]. No significance among groups on all four days
was detected, using a global F-test (overall p = 0.57).
Additional file 3: Figure S3. Histopathology of local invasion and
metastasis of pCB6 tumors. Representative examples of local invasion
and distant metastasis from mammary tumors expressing empty pCB6
vector in experiments from Figures 4 and 5 are shown. Primary tumors
were excised after 21-23 days, and animals were allowed to survive for a
total of 40 days. Primary tumors (Panels A-C), excised previously, and
additional organs (Panels D-H) were retrieved by detailed autopsy and
were processed for histopathological analyses. FFPE processed tissues
were sectioned (5 μm), and stained with hematoxylin and eosin. Images
show the diverse invasive and metastatic characteristics of the pCB6
control tumors, including a suggestion of perineural invasion (Panels A,
B), direct invasion into the fatpad (Panel C), seeding of the small
intestine mesentery and serosal invasion (Panel D), pancreatic invasion
(Panel E), seeding of the splenic capsule (Panel F), and lung metastases
(Panels G and H). Label with “T” indicates primary tumor, “N” indicates
nerve encased by tumor cells, “M” indicates mucosa, “S” indicates serosa,
“P” indicates pancreatic acini, “SC” indicates splenic capsule, and “met”
indicates metastatic nodule. Image magnifications are indicated in lower
right corner of each image.
Abbreviations
3D: 3-dimensional; FFPE: formalin fixed paraffin embedded; HGF: hepatocyte
growth factor; MTT: methylthiazolyldiphenyl-tetrazolium; VSVG: vesicular
stomatitis virus.
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